Pipeline

PRODUCT DEVELOPMENT PIPELINE

TScan is leveraging our proprietary platform technologies to develop a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies with the goal of building our ImmunoBank of TCRs to treat a wide range of tumor types. In addition, we are applying our platform to identify targets and TCRs in therapeutic areas outside of oncology, such as autoimmune disorders and infectious disease.

Name
Indications
DISCOVERY
LEAD OPTIMIZATION
IND-ENABLING
CLINICAL

Liquid Tumor Program

TSC-100
HA-1

Ind-Enabling
AML, MDS, ALL*

TSC-101
HA-2

Ind-Enabling
AML, MDS, ALL*

AML, MDS, ALL*

Solid Tumor Program

TSC-200**
HPV16

Lead Optimization
Head & Neck, Cervical, Anal, NSCLC*, Melanoma

TSC-201
Target-201

Lead Optimization
Head & Neck, Cervical, Anal, NSCLC*, Melanoma

TSC-202
Target-202

Lead Optimization
Head & Neck, Cervical, Anal, NSCLC*, Melanoma

TSC-203
PRAME

Lead Optimization
Head & Neck, Cervical, Anal, NSCLC*, Melanoma

Head & Neck, Cervical, Anal, NSCLC*, Melanoma

TSC-204
MAGE-A1

Lead Optimization

Infectious Disease

Infectious Disease
SARS-CoV-2

Lead Optimization
COVID T cell vaccination

COVID T cell vaccination

*AML: Acute Myeloid Leukemia, MDS: Myelodysplastic Syndrome, ALL: Acute Lymphocytic Leukemia, NSCLC: Non-small cell lung cancer
**TSC-200 will be developed in HPV-positive cancers, which include head & neck, cervical, and anal cancers

Liquid Tumor Program

  • Our liquid tumor program is designed to treat patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplant (HCT), including AML, MDS, and ALL patients where HCT remains standard of care.
  • Despite advances in HCT, up to half of patients relapse following therapy, and relapsing patients face poor prognosis.
  • However, rare patients naturally develop T cells targeting minor histocompatibility antigens such as HA-1 and HA-2, and these patients exhibit lower relapse rates.
  • We are focused on developing TCR-T therapy targeting minor antigens discovered in these patients with exceptional responses to HCT-associated immunotherapy, including HA-1 and HA-2.

Our Clinical Development Strategy for Multiple TCR-T Therapies

  • TScan is leveraging our novel discovery platforms to identify and develop additional minor antigen candidates, expand the addressable patent population for this program, and provide a comprehensive solution for patients.
  • We also plan to evaluate the potential benefit of a multiplexed TCR-T therapy for patients who are positive for both HA-1 and HA-2.

TSC-100 and TSC-101

  • TSC-100 and TSC-101 are HA-1 and HA-2 specific TCR-T therapy candidates directed at eliminating native blood cells, including residual cancer cells, in target-positive and HLA-A*02:01-positive patients undergoing HCT.
  • The TSC-100 and TSC-101 TCRs were identified using ReceptorScan from hundreds of millions of CD8+ T cells.
  • These therapies are designed to elicit an anti-tumor response in patients by targeting HA-1 or HA-2 minor antigens, which are present on malignant and normal blood cells of patients but not on any of the new, donor-derived blood cells.
  • We believe that donor T cells engineered to express an HA-1 or HA-2 specific TCR will generate an anti-tumor effect in patients, leading to a reduction in relapse rates and an increase in long-term survival.

TSC-100 Treatment Paradigm

TSC-102 and beyond

TScan is leveraging its novel discovery platforms to identify and develop additional minor antigen TCRs to expand this program to all patients in need. We have identified a third minor antigen for patients that express the HLA type B*07:02.

In addition to TSC-102, we are continuing to leverage our novel discovery platforms to identify additional minor antigen targets to expand this program and provide a comprehensive solution for patients.

 


 

Solid Tumor Program

  • TScan is concurrently developing a multiplexed TCR-T therapy program to treat solid tumors.
  • Leveraging our disruptive technology platform that enables us to rapidly discover new targets and TCRs directly from the tumor-infiltrating T cells of patients that are actively responding to immunotherapy, we are building a growing ImmunoBank of therapeutically active and safe TCRs with diverse anti-tumor targets.
  • Our vision is that ImmunoBank will be used to provide tailored therapies for patients with various types of solid tumors.
  • Our TCR-T therapies may be multiplexed to help reduce the risk of resistance driven by target loss, MHC downregulation, or mutation of individual HLA genes.
  • To de-risk clinical development of the TCR, we use our TargetScan technology to scan across every peptide sequence in the entire human proteome with the goal of ensuring that it does not have any problematic off-target effects.
  • Targets are both shared among patients with the same cancer type but are also expressed across different solid tumor types, enabling clinical development in multiple indications.

Our Strategy to Treat Solid Tumors with Multiplexed TCR-T Therapy

TSC-200 Program

  • Our TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors.
  • Our first four product candidates include a combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as novel targets for TCR-T therapy, such as TSC-201 and TSC-202.
  • Targets are frequently expressed in high incidence solid tumors, including melanoma, head & neck cancer, NSCLC, and cervical cancer.
  • We are currently advancing our four solid tumor product candidates through lead optimization.
  • We plan to combine these products together as a multiplexed TCR-T treatment to overcome tumor heterogeneity and target loss.

TSC-200 Series Phase I Clinical Strategy

In addition to our four lead product candidates, we have identified over 40 novel antigens based on tumor samples from patients who are actively responding to immunotherapy using our TargetScan technology. As we continue to discover and validate TCR/target pairs, these TCRs will be added to our expanding ImmunoBank, with the long-term goal of providing customized multiplexed TCR-T therapy for virtually any patient with a solid tumor malignancy.

Expansion Opportunities Beyond Oncology

Our primary focus is on the development of T-cell therapies to treat cancer. However, T cells play a fundamental role in many other disease areas, such as infectious disease and autoimmune disease. We believe that our TargetScan technology is well suited to discover novel antigens for the development of therapeutics, diagnostics, and vaccines in these other areas. we intend to build additional corporate value by opportunistically pursuing collaborations with strategic partners for applications of our platform technologies outside our core focus.